title: [An angiographic trial to evaluate the efficacy and safety of tenecteplase in Chinese patients with acute myocardial infarction].
abstract: OBJECTIVE
  In this randomized, open-label, multicenter, angiographic trial, we compared the efficacy and safety of tenecteplase (TNK-tPA) with alteplase (rt-PA) in Chinese patients with acute myocardial infarction.
  
  
  METHODS
  Patients with acute ST-elevation myocardial infarction and pain to hospital time within 6 hours from October 2002, to March 2004 were randomly assigned a body weight-adjusted bolus of TNK-tPA (0.53 mg/kg over more than 10 s, n = 58) or front loaded rt-PA (< or = 100 mg, n = 52). Coronary angiography was performed at 90 min after initiating study drugs. All patients received aspirin and heparin (target activated partial thromboplastin time: 50-70 s). The primary end point of the trial was the rate of TIMI grade 3 flow at 90 minutes. Other end points included the rate of TIMI grade 2/3 flow at 90 minutes, all cause mortality at 30 days, the moderate/severe hemorrhage without intracranial hemorrhage (ICH) and ICH within 30 days.
  
  
  RESULTS
  TIMI grade 3 flow at 90 minutes (68.4% vs. 66.7%, P = 1.00), TIMI grade 2 or 3 at 90 minutes (89.5% vs. 80.4%, P = 0.278), total mortality at 30 days (13.8% vs. 9.6%, P = 0.565), the rate of moderate/severe hemorrhage (8.6% vs. 5.8%, P = 0.72) and incidence of ICH (3.5% vs. 1.9%, P = 1.00) were all similar in TNK-tPA treated patients compared to rt-PA treated patients.
  
  
  CONCLUSIONS
  The efficacy of single-bolus, weight-adjusted TNK-tPA fibrinolytic regimen is equivalent to front-loaded alteplase in terms of the rates of TIMI grade 3 flow, TIMI 2 or 3 flow. Incidences of moderate/severe hemorrhage, ICH and 30-days mortality were similar in TNK-tPA and rt-PA treated patients.
authors.affiliation: Department of Cardiology, Beijing Daxing Hospital, Capital University of Medical Sciences, Beijing 102600, China.
authors.forename: Feng
authors.initials: F
authors.lastname: Liang
authors.forename: Li-zhong
authors.initials: LZ
authors.lastname: Wang
authors.forename: Da-yi
authors.initials: DY
authors.lastname: Hu
authors.forename: Xu-bo
authors.initials: XB
authors.lastname: Shi
authors.forename: Jia-ping
authors.initials: JP
authors.lastname: Wei
authors.forename: Hong
authors.initials: H
authors.lastname: Zhao
authors.forename: Lei
authors.initials: L
authors.lastname: Wang
authors.forename: San-qing
authors.initials: SQ
authors.lastname: Jia
authors.forename: Hong-yu
authors.initials: HY
authors.lastname: Wang
authors.forename: Ru-hui
authors.initials: RH
authors.lastname: Liu
authors.forename: Yun-dai
authors.initials: YD
authors.lastname: Chen
authors.forename: Yan-ling
authors.initials: YL
authors.lastname: Lu
mesh_terms: D000368:Aged; D006801:Humans; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy*; D000077785:Tenecteplase; D015912:Thrombolytic Therapy; D010959:Tissue Plasminogen Activator / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: C104096:TNK-tissue plasminogen activator; D010959:Tissue Plasminogen Activator; D000077785:Tenecteplase